Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.

Abstract: A method, apparatus, system and computer program is provided for controlling an electric power system, including implementation of a voltage control and conservation (VCC) system used to optimally control the independent voltage and capacitor banks using a linear optimization methodology to minimize the losses in the EEDCS and the EUS. An energy validation process system (EVP) is provided which is used to document the savings of the VCC and an EPP is used to optimize improvements to the EEDCS for continuously improving the energy losses in the EEDS. The EVP system measures the improvement in the EEDS a result of operating the VCC system in the “ON” state determining the level of energy conservation achieved by the VCC system. In addition the VCC system monitors pattern recognition events and compares them to the report-by-exception data to detect HVL events.

Abstract: The invention features a prospective respiratory motion compensation technique for cardiovascular magnetic resonance imaging of the whole-heart of a free-breathing subject.

Abstract: The present invention includes compositions and methods for treating T cell lymphomas and leukemias. In certain aspects, the compositions and methods include CAR T cells targeting CD2, CD5, or CD7 and modified cells wherein CD2, CD5, or CD7 has been knocked-out.

Abstract: A reversible tensioning device for an orthotic that includes: a cover; an insert rotatably disposed within the cover; a slot within the cover; a peg fixedly disposed on the insert and slidably located within the slot on the cover, the peg configured to slide between a first end portion and a second end portion of the slot; a spring fixedly attached to the cover and the insert and configured to urge the cover and the insert in opposite rotational directions; a first flange surface on the cover; and a second flange surface on the insert and facing an opposite direction from the first raised surface. The first flange surface and the second flange surface are configured to operably couple with third and fourth flange surfaces on an orthotic device to provide opposing forces on the reversible tensioning device.

Abstract: An assembly for locating footwear to maintain a user's feet in a predetermined therapeutic position, including a bar, typically a unitary curved bar forming an uninterrupted arc, where the bar has a first end and a second end, a first inner locating position on the first end, a first outer locating position on the first end, a second inner locating position on the second end, and a second outer locating position on the second end. Each of the locating positions typically includes a plurality of spaced apart ribs at least partially surrounding in a radial arrangement extending about a center point of a connection hole.

Abstract: A sole attachment assembly for attachment to an orthotic bar having a sole to retain a shoe of a user and a quick release member to couple to an orthotic bar. The sole includes a sole body, a release member receiver, a platform on the receiver, guide wings, a centering projection, and a release button barrier spanning between the guide wings. The quick release member includes a release member body, wings extending laterally from the release member body to slide within the guide wings, a locking tab to keep the quick release member coupled to the shoe sole by interfacing with the quick release button barrier, a locating recess in a top potion of the body configured to provide enhanced stability by interfacing with the platform on the sole, and a centering notch at the front of the body configured to interface with the centering projection on the sole.

Abstract: The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having ?-folate receptor (FR?) binding domain and CD27 costimulatory domain to treat ovarian cancer. In an embodiment, the FR? binding domain is fully human, thereby preventing a host immune response.

Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.

Abstract: A method for providing secure single sign on includes receiving a first data object from an application hosting server, the first data object indicating at least a service provider name and identifying a configuration file corresponding to the service provider name, wherein the configuration file includes at least trusted identity information. The method also includes determining, using the configuration file corresponding to the service provider name, whether the first data object is valid and, in response to a determination that the first data object is valid, generating a response message.

Abstract: The disclosed tamper-evident closure (100) encloses a medical access device (200), such as a vascular access device and includes an actuatable door (127) to create an optional access point (113) for accommodating various arrangements of medical access devices within the tamper-evident closure. The tamper-evident closure comprises a holding cavity (110), an access point into the holding cavity, an actuatable door covering the access point, and a hinge (127c) connecting the actuatable door to the holding cavity.

Abstract: The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having ?-folate receptor (FR?) binding domain and CD27 costimulatory domain to treat ovarian cancer. In an embodiment, the FR? binding domain is fully human, thereby preventing a host immune response.

Abstract: The disclosed tamper-evident closure encloses a medical access device, such as a vascular access device, such that it will be visibly apparent if the medical access device contained in the tamper-evident closure becomes exposed. The tamper-evident closure cannot be reapplied over the medical access device in a way to look the same as it did prior to exposing the medical access device. The tamper-evident closures comprise a securing strap with a first securing strap portion secured to the first part of the tamper-evident closure, a second securing strap portion with a free end for securing to a second part of the tamper-evident closure, and an area of weakness separating the first securing strap portion from the second securing strap portion. The force to break the area of weakness is less than the force to separate the securing strap from the first part or second part.

Abstract: The invention provides specific synthetic chimeric xenonucleic acid guide RNA; s(XNA-gRNA) for enhancing crispr mediated genome editing efficiency. The invention also provides methods and compositions for inducing CRISPR/Cas-based gene editing/regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using single guide RNAs (sgRNAs) that have been chemically modified with xeno nucleic acids which enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a sgRNA that has been chemically modified with xeno nucleic acids to correct a mutation in a target gene associated with the genetic disease.

Abstract: The invention relates to a method for enriching a target polynucleotide sequence containing a genetic variation said method comprising: (a) providing two primers targeted to said target polynucleotide sequence; (b) providing a target specific xenonucleic acid clamp oligomer specific for a wildtype polynucleotide sequence; (c) generating multiple amplicons using PCR under specific temperature cycling conditions; and (d) detecting said amplicons.

Abstract: Compositions and methods for treatment of cancer according to aspects of the present disclosure comprise compounds comprising or consisting of: structural formula (I) or (II) disclosed herein, or a salt, isomer, or derivative thereof.

Abstract: The present invention includes compositions and methods for treating T cell lymphomas and leukemias. In certain aspects, the compositions and methods include CAR T cells targeting CD2, CD5, or CD7 and modified cells wherein CD2, CD5, or CD7 has been knocked-out.

Abstract: Described herein are methods of eliciting an immune response in human subject in need thereof, the methods including transdermally delivering to the human subject a composition comprising particles, the composition contained in a housing of a microneedle patch device, wherein transdermally delivering includes transdermally delivering an initial dose; transdermally delivering a booster dose within 4-6 weeks of the initial dose; and transdermally delivering a subsequent dose at 1 year or more after delivering the booster dose, wherein no dose is given between the booster dose and the subsequent dose. The composition includes particles including an antigenic multilayer film.

Abstract: Compositions and methods for treatment of cancer according to aspects of the present disclosure comprise compounds comprising or consisting of: structural formula (I) or (II) disclosed herein, or a salt, isomer, or derivative thereof.

Abstract: The invention provides a method for detecting KRAS mutations at one or more of codons, said method comprising the steps of: (a) extracting DNA from a biological sample; (b) assaying the DNA via PCR for KRAS mutations at one or more of codons with at least one set of oligonucleotides, wherein the at least one set of oligonucleotides comprises an allele specific forward primer, a reverse primer, a probe and a xenonucleic acid clamp to block amplification of wild type DNA. The xenonucleic acid clamps have aza-aza, thio-aza and oxy-aza chemical functionality.